Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine DOI Creative Commons
Romanee Chaiwarith, Poramed Winichakoon, Parichat Salee

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Nov. 13, 2023

Abstract This study followed healthcare personnel (HCP) who had completed a primary series of CoronaVac and then received the third fourth doses COVID-19 vaccine. The objective was to determine seroconversion rate neutralizing antibodies against wild-type SARS-CoV-2 VOCs at day 28 after dose vaccine prospective cohort conducted Maharaj Nakorn Chiang Mai Hospital, tertiary care hospital affiliated University from July 2021 February 2022. Two hundred eighty-three participants were assessed for eligibility; 142 AZD1222 141 BNT162b2 as dose. Seroconversion rates using 30% inhibition cutoff value 57.2%, 98.6%, 97.8%, 98.9% points before dose, respectively among those receiving Frequencies 31.9%, 99.3%, 98.9%, 100% respectively. B.1.1.529 [Omicron] 76.1% 90.2% (p-value 0.010) 4 weeks in After booster with mRNA vaccine, increased 21.7 91.3% 30.4 No serious safety concerns found this study. In conclusion, antibody responses waned over time regardless regimen. elicited humoral immune response including variants concern, [Omicron], which circulating during period. However, results might not be extrapolated other Omicron sublineages.

Language: Английский

COVID-19 vaccines: A comprehensive review of safety and efficacy DOI
Zhipeng Yan, Ming Yang, Ching‐Lung Lai

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 685 - 777

Published: Jan. 1, 2025

Language: Английский

Citations

0
An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement DOI Creative Commons
Vinícius Pinto Costa Rocha, Helenita Costa Quadros, Antônio Márcio Santana Fernandes

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(7), P. 1504 - 1504

Published: July 5, 2023

SARS-CoV-2 is the etiological agent of coronavirus disease-19 (COVID-19) and responsible for pandemic that started in 2020. The virus enters host cell through interaction its spike glycoprotein with angiotensin converting enzyme-2 (ACE2) on cell’s surface. Antibodies present an important role during infection pathogenesis due to many reasons, including neutralization viruses by binding different epitopes. Therefore, measuring neutralizing antibody titers whole population COVID-19’s epidemiology. Different methods are described literature, some have been used validate main vaccines worldwide. In this review, we discuss quantify titers, their advantages limitations, as well new approaches determineACE2/spike blockage antibodies.

Language: Английский

Citations

10
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines DOI Creative Commons

Camilo C. Roa,

Mari Rose A de Los Reyes,

Eric Plennevaux

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Jan. 11, 2024

We assessed the non-inferiority of homologous boosting compared with heterologous recombinant protein vaccine, SCB-2019, in adults previously immunized different COVID-19 vaccines. Three equal cohorts (N ~ 420) Philippino (18-80 years) Comirnaty, CoronaVac or Vaxzevria vaccines were randomized 1:1 to receive (SCB-2019) boosters. Neutralizing antibodies against prototype SARS-CoV-2 (Wuhan-Hu-1) measured all participants and Delta variant Omicron sub-lineages subsets (30‒50 per arm) 15 days after boosting. Participants recorded solicited adverse events for 7 unsolicited serious until Day 60. Prototype neutralizing responses on SCB-2019 statistically non-inferior boosters, superior CoronaVac, but lower than Comirnaty. BA.1, BA.2, BA.4 BA.5 variants higher Vaxzevria, Responses BF.7, BQ.1.1.3, XBB1.5 following Comirnaty booster significantly booster. reactogenicity was similar Comirnaty; most frequent mild/moderate injection site pain, headache fatigue. No vaccine-related reported. Heterologous well tolerated elicited tested SARS-COV-2 viruses including BA.4, BA.5, that not

Language: Английский

Citations

3
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine DOI Creative Commons
Viravarn Luvira, Punnee Pitisuttithum

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 283 - 293

Published: Feb. 19, 2024

Introduction Inactivated vaccines were delivered to low- and middle-income countries during the early pandemics of COVID-19. Currently, more than 10 inactivated COVID-19 have been developed. Most contain an whole-cell index SARS-CoV-2 strain that is adjuvant. Whole virions with aluminum hydroxide among most commonly used. However, emerging variants waning immunity two doses after 3 months, WHO many local governments recommended booster-dose program especially heterologous platform vaccine.

Language: Английский

Citations

3
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial DOI Creative Commons
Sant Muangnoicharoen,

Rakpong Wiangcharoen,

Saranath Lawpoolsri

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(19), P. 3999 - 4010

Published: May 13, 2024

Inactivated whole-virus vaccination elicits immune responses to both SARS-CoV-2 nucleocapsid (N) and spike (S) proteins, like natural infections. A heterologous Ad26.COV2.S booster given at two different intervals after primary BBIBP-CorV was safe immunogenic days 28 84, with higher observed the longer pre-boost interval. We describe booster-specific hybrid over 1 year.

Language: Английский

Citations

2
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults DOI Creative Commons

Camilo C. Roa,

Mari Rose A de Los Reyes,

Eric Plennevaux

et al.

The Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 228(9), P. 1253 - 1262

Published: July 13, 2023

Abstract Background We compared homologous and heterologous boosting in adults the Philippines primed with 2 or 3 doses of CoronaVac, recombinant protein vaccine, SCB-2019. Methods CoronaVac-immunized (18–72 years) received a full half dose SCB-2019 booster. assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days NAb Delta Omicron variants subsets (30‒50 per arm). Participants recorded adverse events. Results In 2-dose CoronaVac-primed geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182–227) 939 CI, 841–1049) CoronaVac boosters; GMT ratio (4.63; 95% 3.95–5.41) met predefined noninferiority post-hoc superiority criteria. After 3-dose CoronaVac-priming GMTs 279 240–325), 1044 898–1213), 668 520–829) following half-dose boosters, respectively. ratios comparing greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious events reported. Conclusions Full boosters well tolerated superior immunogenicity particularly newly emerged variants. Clinical Trials Registration. NCT05188677.

Language: Английский

Citations

6
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance DOI Creative Commons
Rapisa Nantanee, Peera Jaru-Ampornpan, Napaporn Chantasrisawad

et al.

Vaccine X, Journal Year: 2023, Volume and Issue: 15, P. 100367 - 100367

Published: Aug. 5, 2023

Children 6 months to < 5 years old are recommended receive 3-dose regimen of BNT162b2. previously infected with Omicron variant SARS-CoV-2 develop immunity from natural infection, therefore may require fewer doses vaccine.To compare immunogenicity 1- or 2-dose BNT162b2 in healthy children post COVID-19 COVID-naïve children.Children aged who developed during the Omicron-predominant period were enrolled; Group A 3-6 months(N = 40) and B > prior vaccination. Participants received intramuscularly 1 month apart. enrolled as a control group (N at 0,1,3. Neutralizing antibody against variant(BA.2.75 BA.4/5) was determined by pseudovirus assays(pVNT) reported neutralization dilution for 50%inhibition (ID50) 28 days after 1st 2nd dose.From October-November 2022, 120 median age 2.8 (IQR 1.6-4.0) enrolled. The duration since vaccination 4.4 months(IQR 3.8-5.4) 7.9 months(7.0-8.5) B. In A, geometric means(GMs) pVNT-BA.2.75 ID50 553 (95%CI 338-906) 753(516-1098) 2 doses, respectively, GMs pVNT-BA.4/5 1936(1402-2673) 1885(1414-2512), respectively. B, 1383(1100-1742) 1419 (1104-1823), 2627(2048-3367) 2056(1546-2735), Meanwhile group, 158(98-255) 59(31-114) 3rd dose, mean ratio(GMR) dose compared 3 3.50 (1.93-6.34) 8.74 (4.79-15.95), GMR 2.50 (1.45-4.31).Children variant, robust neutralizing response single-dose an interval infection higher those 3-to-6-month interval.

Language: Английский

Citations

2
Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly DOI
Ömer Acer, Yasemin Genç Bahçe, Osman Özüdoğru

et al.

Current Microbiology, Journal Year: 2024, Volume and Issue: 81(7)

Published: May 13, 2024

Language: Английский

Citations

0
Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results DOI Creative Commons
Joseph Makhema, Emily Shava, Alane Izu

et al.

IJID Regions, Journal Year: 2023, Volume and Issue: 10, P. 35 - 43

Published: Nov. 10, 2023

We report the final analysis of single-arm open-label study evaluating safety and COVID-19 incidence after AZD1222 vaccination in Botswana conducted between September 2021 August 2022.

Language: Английский

Citations

1
Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine DOI Creative Commons
Romanee Chaiwarith, Poramed Winichakoon, Parichat Salee

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Nov. 13, 2023

Abstract This study followed healthcare personnel (HCP) who had completed a primary series of CoronaVac and then received the third fourth doses COVID-19 vaccine. The objective was to determine seroconversion rate neutralizing antibodies against wild-type SARS-CoV-2 VOCs at day 28 after dose vaccine prospective cohort conducted Maharaj Nakorn Chiang Mai Hospital, tertiary care hospital affiliated University from July 2021 February 2022. Two hundred eighty-three participants were assessed for eligibility; 142 AZD1222 141 BNT162b2 as dose. Seroconversion rates using 30% inhibition cutoff value 57.2%, 98.6%, 97.8%, 98.9% points before dose, respectively among those receiving Frequencies 31.9%, 99.3%, 98.9%, 100% respectively. B.1.1.529 [Omicron] 76.1% 90.2% (p-value 0.010) 4 weeks in After booster with mRNA vaccine, increased 21.7 91.3% 30.4 No serious safety concerns found this study. In conclusion, antibody responses waned over time regardless regimen. elicited humoral immune response including variants concern, [Omicron], which circulating during period. However, results might not be extrapolated other Omicron sublineages.

Language: Английский

Citations

0